Compare NICE & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NICE | KYMR |
|---|---|---|
| Founded | 1986 | 2015 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 6.4B |
| IPO Year | 1996 | 2020 |
| Metric | NICE | KYMR |
|---|---|---|
| Price | $106.26 | $72.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 24 |
| Target Price | ★ $162.31 | $105.96 |
| AVG Volume (30 Days) | ★ 751.5K | 740.7K |
| Earning Date | 02-19-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.79 | N/A |
| EPS | ★ 8.79 | N/A |
| Revenue | ★ $2,880,503,000.00 | $43,735,000.00 |
| Revenue This Year | $9.57 | $18.71 |
| Revenue Next Year | $8.07 | N/A |
| P/E Ratio | $11.76 | ★ N/A |
| Revenue Growth | ★ 9.24 | N/A |
| 52 Week Low | $99.00 | $19.45 |
| 52 Week High | $180.61 | $103.00 |
| Indicator | NICE | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 34.72 | 47.75 |
| Support Level | $106.00 | $70.00 |
| Resistance Level | $117.21 | $72.86 |
| Average True Range (ATR) | 3.73 | 3.44 |
| MACD | -0.83 | 0.04 |
| Stochastic Oscillator | 6.79 | 57.69 |
Nice is an enterprise software company that serves the customer engagement and financial crime and compliance markets. Software is deployed primarily on the cloud, but also on premises. Within customer engagement, Nice's CXone is the leading CCaaS platform providing solutions such as call routing, interactive voice response, digital self-service, and workforce engagement management. Within financial crime and compliance, Nice offers risk and investigation management, fraud prevention, anti-money-laundering, and compliance solutions.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.